Inventor
James A. Shayman
Inventor
Ann Arbor, MI, US
Overview
Patents· 25 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes33%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations19%
C07DHeterocyclic compounds16%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms7%
C12YEnzymes7%
G01NInvestigating or analysing materials by determining their chemical or physical properties7%
A01KAnimal husbandry3%
C07KPeptides3%
Y02ATechnologies for adaptation to climate change3%
PatentTitleYear
10,202,340Glucosylceramide synthase inhibitors and therapeutic methods using the same201910,111,937Method of reducing accumulation of intracellular tingible body macrophages20189,309,553'Lysosomal phospholipase A2 (LPLA2) activity as a therapeutic target for treating systemic lupus erythematosus'20168,961,959'Glucosylceramide synthase inhibitors and therapeutic methods using the same'20158,052,970'Lysosomal phospholipase A2 (LPLA2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis'20117,615,573'Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors'20097,582,442'Methods and compositions for using aleveolar macrophage phospholipase A2'20097,335,681'Amino ceramide-like compounds and therapeutic methods of use'20087,319,015'Methods and compositions for using alveolar macrophage phospholipase A2'20087,253,185'Amino ceramide-like compounds and therapeutic methods of use'20077,196,205'Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors'20077,148,251'Amino ceramide-like compounds and therapeutic methods of use'20066,916,802'Amino ceramide-like compounds and therapeutic methods of use'20056,890,949'Amino ceramide-like compounds and therapeutic methods of use'20056,569,889'Amino ceramide-like compounds and therapeutic methods of use'20036,518,259'Compositions for treating autoimmune disease'20036,255,336'Amino ceramide-like compounds and therapeutic methods of use'20016,098,631'Compositions and methods for treating autoimmune disease'20006,051,598'Amino ceramide-like compounds and therapeutic methods of use'20006,040,332'Amino ceramide-like compounds and therapeutic methods of use'20006,030,995'Amino ceramide-like compounds and therapeutic methods of use'20005,952,370'Amino ceramide-like compounds and therapeutic methods of use'19995,945,442'Amino ceramide-like compounds and therapeutic methods of use'19995,916,911'Amino ceramide--like compounds and therapeutic methods of use'19995,302,609'Treatment of diabetic nephropathy'1994Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1994–2016Patents assigned to UNIV MICHIGAN (21)· patent assignee history
1994–2019Based in Ann Arbor, MI, US· patent location history
2007–2009Patents assigned to GENZYME CORP (3)· patent assignee history
2016Patents assigned to ABE AKIRA (1)· patent assignee history
2016Patents assigned to KELLY ROBERT (1)· patent assignee history
2018–2019Patents assigned to UNIV MICHIGAN REGENTS (2)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| UNIV MICHIGAN | 21 | 1994–2016 |
| GENZYME CORP | 3 | 2007–2009 |
| UNIV MICHIGAN REGENTS | 2 | 2018–2019 |
| ABE AKIRA | 1 | 2016 |
| KELLY ROBERT | 1 | 2016 |
Locations
| Location | Patents | Span |
|---|---|---|
| Ann Arbor, MI, US | 25 | 1994–2019 |